



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

## Curriculum Vitae

Personal information **Sari Voutilainen**

### Work experience

---

**Senior Medical Officer, Finnish Medicines Agency (Fimea), Finland**

January 2026 - present

Main activities: Scientific and regulatory assessment of medicinal products

**Oncologist, HUS Comprehensive Cancer Center, Helsinki, Finland**

April 2019 - December 2025

Main activities: Specialist in medical oncology

**Specializing Physician, HUS Comprehensive Cancer Center, Helsinki, Finland**

September 2014 - April 2019

Main activities: Specialist training in medical oncology

**Medical Doctor, City of Helsinki, Laakso Hospital, Finland**

September 2013 - June 2014

Main activities: General medical practice in hospital inpatient setting

**Medical Doctor, Health Care Center of Ylitornio, Finland**

March 2013 - August 2013, August 2014

Main activities: Primary care physician

**Medical Doctor, City of Oulu, Health Care Center of Kaijoharju and Center**

March 2012 - July 2012, September 2012 - February 2013

Main activities: Primary care physician

### Education and training

---

**Doctor of Medicine, University of Helsinki, Finland**

August 2016 - May 2024

**Specialist in Oncology, University of Helsinki**

September 2014 - April 2019

**Licentiate of Medicine, University of Oulu, Finland**

September 2005 - February 2012

### Additional information

---

#### Publications

Roininen N, Takala S, Haapasaari KM, Jukkola-Vuorinen A, Mattson J, Heikkilä P, Karihtala P. Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile. *BMC Cancer*. 2017;17:72.

Roininen N, Takala S, Haapasaari KM, Jukkola-Vuorinen A, Mattson J, Heikkilä P, Karihtala P. Neuroendocrine breast carcinomas share prognostic factors with gastroenteropancreatic neuroendocrine tumors. *Oncology*. 2019;96(3):147-155.

Takala S, Heikkilä P, Nevanlinna H, Blomqvist C, Mattson J. Metaplastic carcinoma of the breast: Prognosis and response to systemic treatment in metastatic disease. *Breast J.* 2019;25(3):418-424.

Voutilainen S, Heikkilä P, Sampo M, Nevanlinna H, Blomqvist C, Mattson J. Expression of markers of stem cell characteristics, epithelial-mesenchymal transition, basal-like phenotype, proliferation and androgen receptor in metaplastic breast cancer and their prognostic impact. *Acta Oncol.* 2021;60:1-7.

Voutilainen S, Heikkilä P, Bartkova J, Nevanlinna H, Blomqvist C, Bartek J, Mattson J. Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in metaplastic carcinoma of the breast. *BMC Cancer.* 2022;22:1298.

Karihtala P, Porvari K, Roininen N, Voutilainen S, Mattson J, Heikkilä P, Haapasaari KM, Selander K. Comparison of mutational profiles of neuroendocrine breast tumours, invasive ductal carcinomas and pancreatic neuroendocrine carcinomas. *Oncogenesis.* 2022;11:53.

Voutilainen S. Characteristics of metaplastic breast carcinoma. Doctoral dissertation, University of Helsinki, Helsinki, Finland, 2023.

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)